The Cambridge Pulmonary Hypertension Outcome Review (CAMPHOR): a measure of health-related quality of life and quality of life for patients with pulmonary hypertension
- PMID:16411035
- DOI:10.1007/s11136-005-3513-4
The Cambridge Pulmonary Hypertension Outcome Review (CAMPHOR): a measure of health-related quality of life and quality of life for patients with pulmonary hypertension
Abstract
Objective:No outcome measures specific to pulmonary hypertension (PH) currently exist. The aim of the study was to develop health-related quality of life (symptoms and functioning) scales and a quality of life scale that would allow comprehensive, accurate and valid patient-reported outcome assessment in clinical studies.
Methods:The content of the Cambridge Pulmonary Hypertension Outcome Review (CAMPHOR) was derived from qualitative interviews conducted with 35 patients. Item reduction was based on the analysis of responses to a postal survey (n=75) and patient interviews (n=15) designed to determine face and content validity. A final postal validation study (n=91) was performed to determine reproducibility and construct validity.
Results:The questionnaire was well received by participants who found it to be relevant, comprehensible and quick and easy to complete. Rasch and factor analyses were conducted to ensure unidimensionality of the final CAMPHOR scales; Overall symptoms (made up of Energy, Breathlessness and Mood subscales), Functioning and Quality of life. The CAMPHOR scales had good internal consistency (alpha=0.90-0.92) and reproducibility (test-retest correlations=0.86-0.92). They also exhibited convergent, divergent and known groups validity.
Conclusions:The CAMPHOR is a valuable new instrument for assessing patient-reported outcome in PH clinical trials and routine practice.
Similar articles
-
Adaptation and validation of the Cambridge pulmonary hypertension outcome review for Sweden.Scand J Public Health. 2012 Dec;40(8):777-83. doi: 10.1177/1403494812464445. Epub 2012 Oct 31. Scand J Public Health. 2012. PMID:23117210
-
Portuguese validation of the Cambridge pulmonary hypertension outcome review (CAMPHOR) questionnaire.Health Qual Life Outcomes. 2016 Jul 26;14(1):110. doi: 10.1186/s12955-016-0513-8. Health Qual Life Outcomes. 2016. PMID:27460644 Free PMC article.
-
Adaptation and Validation of the Cambridge Pulmonary Hypertension Outcome Review (CAMPHOR) for Use in Spain.牧师Esp心功能杂志(英格兰)。2017年6月,70(6):467 - 473。doi: 10.1016/j.rec.2016.11.007. Epub 2016 Dec 15. 牧师Esp心功能杂志(英格兰)。2017. PMID:27989660 Review. English, Spanish.
-
ADAPTATION AND VALIDATION OF THE CAMBRIDGE PULMONARY HYPERTENSION OUTCOME REVIEW (CAMPHOR) FOR CROATIA.Acta Clin Croat. 2019 Mar;58(1):3-12. doi: 10.20471/acc.2019.58.01.01. Acta Clin Croat. 2019. PMID:31363319 Free PMC article.
-
Adaptation of the Cambridge Pulmonary Hypertension Outcome Review (CAMPHOR) into French-Canadian and English-Canadian.Can Respir J. 2008 Mar;15(2):77-83. doi: 10.1155/2008/767126. Can Respir J. 2008. PMID:18354747 Free PMC article. Review.
Cited by
-
Patient Satisfaction with a Dedicated Infusion Pump for Subcutaneous Treprostinil to Treat Pulmonary Arterial Hypertension.J Pers Med. 2023 Feb 26;13(3):423. doi: 10.3390/jpm13030423. J Pers Med. 2023. PMID:36983605 Free PMC article.
-
Functional capacity testing in patients with pulmonary hypertension (PH) using the one-minute sit-to-stand test (1-min STST).PLoS One. 2023 Mar 9;18(3):e0282697. doi: 10.1371/journal.pone.0282697. eCollection 2023. PLoS One. 2023. PMID:36893125 Free PMC article.
-
Concerns with Patient Reported Outcome Measurement and Value Claims for Therapy Response: The Case of Mavacamten and Symptomatic Hypertrophic Cardiomyopathy (SHCM).Innov Pharm. 2022 Dec 12;13(2):10.24926/iip.v13i2.4861. doi: 10.24926/iip.v13i2.4861. eCollection 2022. Innov Pharm. 2022. PMID:36654699 Free PMC article.
-
Effects of COVID-19 pandemic on the management of pulmonary hypertension.Respir Med. 2023 Jan;206:107061. doi: 10.1016/j.rmed.2022.107061. Epub 2022 Nov 26. 和地中海》2023。 PMID:36493604 Free PMC article.
-
Growth differentiation factor 11 induces skeletal muscle atrophy via a STAT3-dependent mechanism in pulmonary arterial hypertension.Skelet Muscle. 2022 May 6;12(1):10. doi: 10.1186/s13395-022-00292-x. Skelet Muscle. 2022. PMID:35524286 Free PMC article.
References
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical